Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 5Terminated 3Recruiting 3Unknown 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 283Lymphoid 14Other solid neoplasm 11Thoracic 6Tumor-Agnostic 4Head & Neck 2Gynecologic 2Breast 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Other 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Melanoma 1

Interventions

Nivolumab 25pembrolizumab 21Ipilimumab 15Temozolomide 13toripalimab 12Biopsy 10Imiquimod 8Cyclophosphamide 8Dacarbazine 7Blood Specimen Collection 7camrelizumab 6Chemotherapy, Adjuvant 6trametinib 5dabrafenib 5atezolizumab 5aldesleukin 5Gene Expression Profiling 5Cisplatin 5Aminolevulinic Acid 5fludarabine phosphate 4fludarabine 4durvalumab 4binimetinib 4apatinib 4Tomography, Optical Coherence 4Sorafenib 4Photochemotherapy 4Injections 4Bevacizumab 4tislelizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Oxaliplatin × Dermatologic × Clear all
NCT00538005 2014-01-10

Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

National Cancer Institute (NCI)

Phase 1/2 Unknown
54 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡